Article

MICS has benefits for surgeon and patient, says speaker

Because microincisional cataract surgery permits the use of smaller incisions than those employed in conventional phacoemulsification, it is potentially a safer procedure, offering greater control to the surgeon; also, it may yield less astigmatism, less inflammation, and quicker healing for the patient, according to one surgeon.

Key Points

New Orleans-Because microincisional cataract surgery (MICS) permits the use of smaller incisions than those employed in conventional phacoemulsification, it is potentially a safer procedure, offering greater control to the surgeon; also, it may yield less astigmatism, less inflammation, and quicker healing for the patient, said Louis D. "Skip" Nichamin, MD, at the annual meeting of the American Academy of Ophthalmology.

"I do believe that MICS in some form is something that we all really ought to be very excited about," Dr. Nichamin, medical director of the Laurel Eye Clinic, Brookville, PA, told attendees.

All of the major phaco platforms soon will be facilitating incisions in the 2-mm range, he added. "Microincisional IOL implants are a reality and are going to be here soon," Dr. Nichamin said, so a surgeon will not need to enlarge an incision to accommodate IOL insertion.

"Obviously, safety is going to be paramount, and ease by which we can adopt these techniques," Dr. Nichamin said. "We're certainly not going to surrender any control over the intraocular milieu for these smaller incisions, nor am I personally willing to allow efficiency to suffer." Additional considerations include cost and visual outcomes, he said, noting that more data are needed regarding the latter issue.

Smaller incisions

"At this juncture, what can we say about MICS? What does it bring to the table?" Dr. Nichamin asked rhetorically. "Obviously, smaller incisions. And I know we always have the argument of diminishing returns, but I would submit to you that smaller is always better. We have an unmitigated desire to achieve smaller incisions, because smaller is safer. Specifically, it's easier to create an incision that is as deep as it is wide.

"Smaller wounds also ought to lend more control, but that means they have to be watertight and not distorted and leaky," he added. "Of course, we know a smaller incision yields less astigmatism, and we would expect that less trauma leads to less inflammation and quicker healing" than that seen with the larger incisions used in conventional phaco.

Clear corneal incisions have been associated with a greater incidence of endophthalmitis than that seen with sclerocorneal tunnel incisions, said Dr. Nichamin, referencing a white paper released by the American Society of Cataract and Refractive Surgery's Cataract Clinical Committee (J Cataract Refract Surg. 2006;32:1556-1559). "We acknowledge that this was a multifactorial, complex problem, but at the root of the story is the fact that clear corneal incisions are less forgiving. They're harder to create. So with MICS, we can have a smaller incision that we can make in a way that is more square, as Paul Ernest has advocated, and that's a good thing."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.